DoD Breast Cancer Clinical Research Extension Award | HT942525BCRPCREA

Opportunity Information: Apply for HT942525BCRPCREA

The DoD Breast Cancer Clinical Research Extension Award (FY25) is a U.S. Department of Defense Breast Cancer Research Program (BCRP) grant designed to help existing breast cancer clinical studies deliver more complete and clinically useful results. Instead of primarily funding brand-new trials, this opportunity focuses on extending or expanding work that is already underway or was previously conducted, especially in situations where important information is at risk of being lost. The central idea is to make the time and effort contributed by participating patients count for more by strengthening follow-up, improving the completeness of data and biospecimen collection, and supporting additional analyses that can increase the real-world clinical impact of the study.

This award specifically targets common reasons clinical research ends up underpowered or less informative than intended, such as early termination of a trial, limited duration of patient follow-up, or gaps in sample collection and data capture. Projects under this mechanism can include longer-term outcomes tracking, additional timepoints of data collection, completion or enhancement of biospecimen acquisition, and deeper or more refined analyses of existing datasets and samples. In practical terms, the program is trying to close the loop on studies that may already have generated valuable signals but need more time, more complete datasets, or stronger analyses to translate those signals into knowledge that can affect patient care, clinical decision-making, or future trial design.

Applicants are expected to align their proposed work with at least one of the FY25 BCRP overarching challenges, unless they provide a well-supported justification for why an exception is warranted. While the specific list of those challenges is not included in the text provided, the requirement signals that proposals should clearly connect the extension work to high-priority problems recognized by the BCRP for that fiscal year, rather than extending a study in a way that is scientifically interesting but not clearly tied to the program's stated needs.

A distinctive feature of this opportunity is the required involvement of patient voice in a formal and meaningful way. The research team must include two or more breast cancer consumer advocates. This requirement is intended to ensure that patient perspectives help shape the project, including the relevance of research questions, the acceptability and feasibility of follow-up procedures, and the interpretation and communication of outcomes that matter to people living with and beyond breast cancer.

The grant also offers flexibility in leadership structure. Applications may be submitted by a single Principal Investigator (PI) or through a two-PI Partnering PI Option (PPIO), where the two PIs are designated as an Initiating PI and a Partnering PI. Under the partnering model, the Initiating PI submits the pre-application, but at the full application stage both the initiating and partnering applications must be submitted. The solicitation emphasizes that an application can be withdrawn if both components are not submitted by the full application deadline, or if either the initiating or partnering submission is administratively withdrawn, making coordination and compliance between the two institutions or teams essential.

Administratively, this is a discretionary grant opportunity run by the Department of the Army, U.S. Army Medical Research Acquisition Activity (USAMRAA), within the Science and Technology and other Research and Development activity category (CFDA 12.420). Eligibility is listed as unrestricted, meaning the program is broadly open to applicant types unless otherwise limited by the full solicitation. The opportunity number is HT942525BCRPCREA, the posting (creation) date is April 22, 2025, and the original closing date is June 27, 2025. The notice anticipates making about three awards, and an award ceiling is not specified in the provided excerpt.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Breast Cancer Clinical Research Extension Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2025-04-22.
• Applicants must submit their applications by 2025-06-27. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 3 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942525BCRPCREA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: